Clinical and hormonal aspects of pancreatic diabetes.
The prevalence of diabetes due to chronic pancreatitis would appear to be increasing. In western countries this is associated with the known increase in alcohol consumption and AIP. Malnutrition may be etiologic in tropical areas. The incidence of diabetes in chronic pancreatitis is dependent on a number of factors. It is more common in alcohol-induced pancreatitis, rarely occurs after the first attack but tends to increase with time and rises markedly in calcific pancreatitis. Abnormal glucose tolerance occurred in 91% of patients with calcific pancreatitis and 70% of patients with noncalific AIP in our follow up of five to 12 years. This stresses the importance of serial regular glucose tolerance tests in these patients (Table I). The insulin-reserve is severely depleted in most patients who do not yet demonstrate abnormal glucose tolerance, indicating that pancreatitis regularly affects the islets and that nearly all patients are potential diabetics. The beta cells appear to respond better to oral glucose, glucagon or secretin than to i.v. glucose suggesting a selective glucose receptor loss or block to hyperglycemia in chronic pancreatitis. The alpha cells seem to be more resistant to the effects of chronic pancreatitis but true hypoglucagonemia was found in 16% of patients. In addition, stimulated growth hormone secretion may be deficient in pancreatic diabetes. These last two factors, among others, may be responsible for the protracted and even fatal hypoglycemia to which some patients with AIP on insulin therapy are liable. The danger of drug-induced hypoglycemia, coupled with the infrequency of vasculopathy, retinopathy and nephropathy in pancreatic diabetes has induced us to keep these patients hyperglycemic and glycosuric rather than in a sugar-free state, as long as symptoms are contained. Recurrent abdominal pain, marked weight loss and associated steatorrhea often raise special problems in the management of the pancreatic diabetic.
D000208:Acute Disease; D000437:Alcoholism / Q000150:complications; D002114:Calcinosis / Q000150:complications; D002769:Cholelithiasis / Q000150:complications; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000209:etiology; D003926:Diabetic Coma / Q000209:etiology; D016883:Diabetic Ketoacidosis / Q000150:complications; D003929:Diabetic Neuropathies / Q000209:etiology; D005934:Glucagon / Q000097:blood; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010195:Pancreatitis / Q000150:complications* / Q000209:etiology / Q000503:physiopathology; D014397:Tuberculosis, Pulmonary / Q000150:complications
D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon